Back to Search Start Over

Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.

Authors :
Haffner CD
Charnley AK
Aquino CJ
Casillas L
Convery MA
Cox JA
Elban MA
Goodwin NC
Gough PJ
Haile PA
Hughes TV
Knapp-Reed B
Kreatsoulas C
Lakdawala AS
Li H
Lian Y
Lipshutz D
Mehlmann JF
Ouellette M
Romano J
Shewchuk L
Shu A
Votta BJ
Zhou H
Bertin J
Marquis RW
Source :
ACS medicinal chemistry letters [ACS Med Chem Lett] 2019 Oct 11; Vol. 10 (11), pp. 1518-1523. Date of Electronic Publication: 2019 Oct 11 (Print Publication: 2019).
Publication Year :
2019

Abstract

Herein we report the discovery of pyrazolocarboxamides as novel, potent, and kinase selective inhibitors of receptor interacting protein 2 kinase (RIP2). Fragment based screening and design principles led to the identification of the inhibitor series, and X-ray crystallography was used to inform key structural changes. Through key substitutions about the N1 and C5 N positions on the pyrazole ring significant kinase selectivity and potency were achieved. Bridged bicyclic pyrazolocarboxamide 11 represents a selective and potent inhibitor of RIP2 and will allow for a more detailed investigation of RIP2 inhibition as a therapeutic target for autoinflammatory disorders.<br />Competing Interests: The authors declare no competing financial interest.<br /> (Copyright © 2019 American Chemical Society.)

Details

Language :
English
ISSN :
1948-5875
Volume :
10
Issue :
11
Database :
MEDLINE
Journal :
ACS medicinal chemistry letters
Publication Type :
Academic Journal
Accession number :
31749904
Full Text :
https://doi.org/10.1021/acsmedchemlett.9b00141